MedTrace Logo

89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors

NCT01338090 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 14

Last updated 2012-04-03

No results posted yet for this study

Summary

This is a pilot study for evaluation of 89Zr-bevacizumab PET imaging as predictive biomarker during treatment with everolimus in patients with neuroendocrine tumors.

Patients with progressive disease during the last year will receive treatment with everolimus 10 mg/day orally and 89Zr-bevacizumab PET imaging will be performed before start of treatment and after 2 and 12 weeks of treatment in the first three patients. If the scan after 2 weeks of treatment is already informative further patients will not undergo a scan at 12 weeks. A scan is considered already informative if both scans show at least 30% decrease in uptake in case of response, or at least 30% increase in uptake in case of disease progression.

Four days before the scan patients will be injected intravenously 37 MBq, protein dose 5 mg 89Zr-bevacizumab. At day 1, day 15 and day 99, PET images will be made for visualization and quantification of VEGF in the tumor lesions and blood will be drawn for determination of angiogenesis and mTOR pathway related biomarkers.

Conditions

Interventions

DRUG

89Zr-bevacizumab

Intravenous injection 120 MBq

DRUG

Everolimus

Oral use, 10 mg per day

Sponsors & Collaborators

Principal Investigators

  • Elisabeth GE de Vries, MD, PHD · University Medical Center Groningen

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01338090 on ClinicalTrials.gov